Related Experiment Videos

[How to select newly-developed oral inotropic agents: an evaluation based on their effects on heart rate and

K Fukuda1, S Handa, S Ogawa

  • 1Department of Medicine, Keio University, Tokyo.

Journal of Cardiology
|January 1, 1990
PubMed

Insights

New oral inotropic agents were evaluated for heart rate and arrhythmia effects in dilated cardiomyopathy patients. OPC-8212 showed ideal inotropic effects without impacting heart rate, unlike denopamine and xamoterol.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Idiopathic dilated cardiomyopathy (IDCM) requires effective oral inotropic agents.
  • Assessing chronotropic and arrhythmogenic effects is crucial for agent selection.

Purpose of the Study:

  • To evaluate the chronotropic and arrhythmogenic effects of novel oral inotropic agents in IDCM patients.
  • To compare denopamine, xamoterol, and OPC-8212 in terms of heart rate and arrhythmia changes.

Main Methods:

  • 60 IDCM patients (NYHA class II-IV) received sequential oral denopamine, xamoterol, and OPC-8212.
  • Ambulatory electrocardiography monitored heart rate and arrhythmias over 10 +/- 2 months.

Main Results:

  • Denopamine slightly increased heart rate; 60 mg caused tachycardia in atrial fibrillation.
  • Xamoterol altered heart rate patterns (daytime decrease, nighttime increase) and benefited some atrial fibrillation patients, but worsened heart failure in two NYHA class IV patients.
  • OPC-8212 did not affect heart rate and was considered ideal.
  • No agents aggravated arrhythmias or caused sustained ventricular tachycardia.

Conclusions:

  • Inotropic agent selection for IDCM should consider heart failure severity, chronotropic, and arrhythmogenic effects.
  • OPC-8212 presents as a promising inotropic agent due to its neutral effect on heart rate.

Related Concept Videos